DYRK1B and cancer: Increased DYRK1A expression was described in Down syndrome, while elevated DYRK1B levels were reported in solid tumors, such as gastrointestinal tumors or lung cancer [9], and acts as a negative cell cycle regulator in many tissues (e.g., by enhancing the resistance of cancer cells to chemotherapy) [15].